Melanoma cells frequently adopt a bleb-driven amoeboid migration mode to traverse confined tissue microenvironments, a behavior that facilitates metastatic dissemination. The source study used a morphology-based screening approach to uncover regulators of this amoeboid phenotype and to identify existing drugs that can suppress it. The authors emphasize an unexpected role for peripheral serotonin signaling in controlling the biomechanics of bleb formation and sustained amoeboid motility in melanoma.
Using a morphology-focused drug repurposing screen, the investigators identified the anti-migraine agent dihydroergotamine (DHE) as a potent inhibitor of amoeboid behavior in melanoma cells. According to the source, DHE suppresses the bleb-driven migratory phenotype; detailed screening parameters, concentrations, cell lines used, and assay conditions were not reported in the abstract and therefore are not available here.
Mechanistic follow-up in the report attributes DHE’s anti-amoeboid effect to its activity on serotonin receptors, with 5-HTR7 highlighted as the primary receptor mediating this pathway. The authors report that trace levels of peripheral serotonin can activate 5-HTR7 on melanoma cells. Activation of this receptor is described as an upstream trigger for intracellular signaling that supports the cortical contractility necessary for blebbing.
Activation of 5-HTR7 by peripheral serotonin is reported to stimulate the cAMP/PKA signaling axis and engage ROCK signaling. This combined signaling cascade increases cortical contractility, a mechanical requirement to generate and sustain plasma membrane blebs. The source explicitly links the receptor–second-messenger pathway (5-HTR7→cAMP/PKA) and ROCK-dependent changes in acto-myosin contractility to the cellular mechanics underlying amoeboid migration.
The study reports that pharmacologic perturbation of this pathway reduces confined migration while leaving proliferation unaffected. Specifically, either DHE treatment or direct PKA inhibition significantly impaired the ability of melanoma cells to migrate under confinement. The source notes that these interventions did not alter cell proliferation, indicating a selective effect on motility rather than cell growth. Exact experimental readouts and quantitative results are not provided in the abstract.
Analyzing clinical data, the authors report that elevated levels of serotonin-degrading enzymes, such as MAOB, correlate with more favorable patient prognoses. Conversely, expression of these serotonin-degrading enzymes is reduced in metastatic lesions compared with non-metastatic contexts, according to the source. These observations are presented as clinical support for a model in which higher extracellular serotonin or decreased serotonin degradation may promote amoeboid motility and metastatic competence in melanoma.
The findings identify serotonin receptors, and specifically 5-HTR7, as actionable targets to limit bleb-based amoeboid migration in melanoma. Repurposing of DHE is proposed as a potential strategy to interfere with this pro-migratory signaling axis, and modulation of cAMP/PKA or ROCK pathways is highlighted as complementary mechanistic entry points.
Limitations and gaps in the source material: the article is a preprint and has not been peer reviewed. The abstract does not report experimental details such as cell models, in vivo validation, drug concentrations, time courses, statistical metrics, or potential off-target effects. Those methodological and quantitative data are therefore not available from the provided source text and should be consulted in the full preprint for critical evaluation.
In summary, the study presents a mechanistic link between peripheral serotonin, 5-HTR7 activation, and downstream cAMP/PKA–ROCK signaling that promotes cortical contractility and bleb-driven amoeboid migration in melanoma. Pharmacologic blockade with DHE or inhibition of PKA impairs confined migration without affecting proliferation, and clinical correlations with MAOB expression suggest relevance to patient outcomes. These observations support further preclinical and clinical investigation into serotonin signaling modulators as strategies to limit melanoma metastatic spread.